APO RESEARCH · REPORT
Covid-19 Treatment
Patients today have more treatment options in the battle against coronavirus disease.
Product & engineering
Understand the product.
Patients today have more treatment options in the battle against coronavirus disease.
In November 2020, the FDA granted emergency use authorization to two monoclonal antibody treatments (bamlanivimab, made by Eli Lilly; and a combination of casirivimab and imdevimab, made by Regeneron). Both treatments have been approved for non-hospitalized adults and children over age 12 with mild to moderate COVID-19 symptoms who are at risk for developing severe COVID-19 or being hospitalized for it. In these patients, the approved treatments can reduce the risk of hospitalization and emergency room visits. These therapies must be given intravenously (by IV) soon after developing symptoms.
The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19 who are sick enough to need hospitalization. Veklury should only be administered in a hospital or in a health care setting capable of providing acute care comparable to inpatient hospital care.
The Drugs for Covid-19: Dexamethasone, Tocilizumab, Remdesivir, Baricitinib in combination with remdesivir, Anticoagulation drugs ("blood thinners"), etc.
In August 2020, the FDA issued an emergency use authorization (EUA) for convalescent plasma in patients hospitalized with COVID-19.
In this report, we study all treatment method for Covid-19.
Selected research
Industry Research
Covid-19 Treatment Industry Research Report 2026
Market perspective
Patients today have more treatment options in the battle against coronavirus disease.
In November 2020, the FDA granted emergency use authorization to two monoclonal antibody treatments (bamlanivimab, made by Eli Lilly; and a combination of casirivimab and imdevimab, made by Regeneron). Both treatments have been approved for non-hospitalized adults and children over age 12 with mild to moderate COVID-19 symptoms who are at risk for developing severe COVID-19 or being hospitalized for it. In these patients, the approved treatments can reduce the risk of hospitalization and emergency room visits. These therapies must be given intravenously (by IV) soon after developing symptoms.
The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19 who are sick enough to need hospitalization. Veklury should only be administered in a hospital or in a health care setting capable of providing acute care comparable to inpatient hospital care.
Read the full market overview
The Drugs for Covid-19: Dexamethasone, Tocilizumab, Remdesivir, Baricitinib in combination with remdesivir, Anticoagulation drugs ("blood thinners"), etc.
In August 2020, the FDA issued an emergency use authorization (EUA) for convalescent plasma in patients hospitalized with COVID-19.
In this report, we study all treatment method for Covid-19.
Global core covid-19 treatment manufacturers include Cadila Healthcare, Novartis etc.The top 2 companies hold a share about 30%.North America is the largest market, with a share about 47%, followed by Europe and Asia Pacific with the share about 30% and 9%.
Report Scope
This report quantifies the global Covid-19 Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Covid-19 Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Covid-19 Treatment Market by Company
Cadila Healthcare
Johnson & Johnson
ImmunoPrecise
Novartis
AstraZeneca
Cipla
AbbVie
Bayer
Regeneron Pharmaceuticals
Ascletis Pharma
GlaxoSmithKline
Gilead Sciences
Pharmstandard
Fujifilm Holdings
Zhejiang Hisun Pharmaceutical Co. Ltd
Roche
Sanofi
Pfizer
Eli Lilly
Covid-19 Treatment Segment by Type
Life Support
Antiviral Medicine
Antibody Treatments
Others
Covid-19 Treatment Segment by End User
Children
Adult
Covid-19 Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Covid-19 Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Covid-19 Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Covid-19 Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Covid-19 Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Life Support
- Antiviral Medicine
- Antibody Treatments
- Others
Applications
- Children
- Adult
Companies covered
- Cadila Healthcare
- Johnson & Johnson
- ImmunoPrecise
- Novartis
- AstraZeneca
- Cipla
- AbbVie
- Bayer
- Regeneron Pharmaceuticals
- Ascletis Pharma
- GlaxoSmithKline
- Gilead Sciences
- Pharmstandard
- Fujifilm Holdings
- Zhejiang Hisun Pharmaceutical Co. Ltd
- Roche
- Sanofi
- Pfizer
- Eli Lilly
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Covid-19 Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Life Support
- 2.2.3 Antiviral Medicine
- 2.2.4 Antibody Treatments
- 2.2.5 Others
- 2.3 Covid-19 Treatment by End User
- 2.3.1 Market Value Comparison by End User (2021 VS 2025 VS 2032)
- 2.3.2 Children
- 2.3.3 Adult
- 2.4 Assumptions and Limitations
3 Covid-19 Treatment Breakdown Data by Type
- 3.1 Global Covid-19 Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Covid-19 Treatment Forecasted Market Size by Type (2027-2032)
4 Covid-19 Treatment Breakdown Data by End User
- 4.1 Global Covid-19 Treatment Historic Market Size by End User (2021-2026)
- 4.2 Global Covid-19 Treatment Forecasted Market Size by End User (2027-2032)
5 Global Growth Trends
- 5.1 Global Covid-19 Treatment Market Perspective (2021-2032)
- 5.2 Global Covid-19 Treatment Growth Trends by Region
- 5.2.1 Global Covid-19 Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Covid-19 Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Covid-19 Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Covid-19 Treatment Market Dynamics
- 5.3.1 Covid-19 Treatment Industry Trends
- 5.3.2 Covid-19 Treatment Market Drivers
- 5.3.3 Covid-19 Treatment Market Challenges
- 5.3.4 Covid-19 Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Covid-19 Treatment Players by Revenue
- 6.1.1 Global Top Covid-19 Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Covid-19 Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Covid-19 Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Covid-19 Treatment Head Office and Area Served
- 6.4 Global Covid-19 Treatment Players, Product Type & Application
- 6.5 Global Covid-19 Treatment Manufacturers Established Date
- 6.6 Global Covid-19 Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Covid-19 Treatment Market Size (2021-2032)
- 7.2 North America Covid-19 Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Covid-19 Treatment Market Size by Country (2021-2026)
- 7.4 North America Covid-19 Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Covid-19 Treatment Market Size (2021-2032)
- 8.2 Europe Covid-19 Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Covid-19 Treatment Market Size by Country (2021-2026)
- 8.4 Europe Covid-19 Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Covid-19 Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Covid-19 Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Covid-19 Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Covid-19 Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Covid-19 Treatment Market Size (2021-2032)
- 10.2 South America Covid-19 Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Covid-19 Treatment Market Size by Country (2021-2026)
- 10.4 South America Covid-19 Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Covid-19 Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Covid-19 Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Covid-19 Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Covid-19 Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Cadila Healthcare
- 12.1.1 Cadila Healthcare Company Information
- 12.1.2 Cadila Healthcare Business Overview
- 12.1.3 Cadila Healthcare Revenue in Covid-19 Treatment Business (2021-2026)
- 12.1.4 Cadila Healthcare Covid-19 Treatment Product Portfolio
- 12.1.5 Cadila Healthcare Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Covid-19 Treatment Business (2021-2026)
- 12.2.4 Johnson & Johnson Covid-19 Treatment Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 ImmunoPrecise
- 12.3.1 ImmunoPrecise Company Information
- 12.3.2 ImmunoPrecise Business Overview
- 12.3.3 ImmunoPrecise Revenue in Covid-19 Treatment Business (2021-2026)
- 12.3.4 ImmunoPrecise Covid-19 Treatment Product Portfolio
- 12.3.5 ImmunoPrecise Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Covid-19 Treatment Business (2021-2026)
- 12.4.4 Novartis Covid-19 Treatment Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in Covid-19 Treatment Business (2021-2026)
- 12.5.4 AstraZeneca Covid-19 Treatment Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 Cipla
- 12.6.1 Cipla Company Information
- 12.6.2 Cipla Business Overview
- 12.6.3 Cipla Revenue in Covid-19 Treatment Business (2021-2026)
- 12.6.4 Cipla Covid-19 Treatment Product Portfolio
- 12.6.5 Cipla Recent Developments
- 12.7 AbbVie
- 12.7.1 AbbVie Company Information
- 12.7.2 AbbVie Business Overview
- 12.7.3 AbbVie Revenue in Covid-19 Treatment Business (2021-2026)
- 12.7.4 AbbVie Covid-19 Treatment Product Portfolio
- 12.7.5 AbbVie Recent Developments
- 12.8 Bayer
- 12.8.1 Bayer Company Information
- 12.8.2 Bayer Business Overview
- 12.8.3 Bayer Revenue in Covid-19 Treatment Business (2021-2026)
- 12.8.4 Bayer Covid-19 Treatment Product Portfolio
- 12.8.5 Bayer Recent Developments
- 12.9 Regeneron Pharmaceuticals
- 12.9.1 Regeneron Pharmaceuticals Company Information
- 12.9.2 Regeneron Pharmaceuticals Business Overview
- 12.9.3 Regeneron Pharmaceuticals Revenue in Covid-19 Treatment Business (2021-2026)
- 12.9.4 Regeneron Pharmaceuticals Covid-19 Treatment Product Portfolio
- 12.9.5 Regeneron Pharmaceuticals Recent Developments
- 12.10 Ascletis Pharma
- 12.10.1 Ascletis Pharma Company Information
- 12.10.2 Ascletis Pharma Business Overview
- 12.10.3 Ascletis Pharma Revenue in Covid-19 Treatment Business (2021-2026)
- 12.10.4 Ascletis Pharma Covid-19 Treatment Product Portfolio
- 12.10.5 Ascletis Pharma Recent Developments
- 12.11 GlaxoSmithKline
- 12.11.1 GlaxoSmithKline Company Information
- 12.11.2 GlaxoSmithKline Business Overview
- 12.11.3 GlaxoSmithKline Revenue in Covid-19 Treatment Business (2021-2026)
- 12.11.4 GlaxoSmithKline Covid-19 Treatment Product Portfolio
- 12.11.5 GlaxoSmithKline Recent Developments
- 12.12 Gilead Sciences
- 12.12.1 Gilead Sciences Company Information
- 12.12.2 Gilead Sciences Business Overview
- 12.12.3 Gilead Sciences Revenue in Covid-19 Treatment Business (2021-2026)
- 12.12.4 Gilead Sciences Covid-19 Treatment Product Portfolio
- 12.12.5 Gilead Sciences Recent Developments
- 12.13 Pharmstandard
- 12.13.1 Pharmstandard Company Information
- 12.13.2 Pharmstandard Business Overview
- 12.13.3 Pharmstandard Revenue in Covid-19 Treatment Business (2021-2026)
- 12.13.4 Pharmstandard Covid-19 Treatment Product Portfolio
- 12.13.5 Pharmstandard Recent Developments
- 12.14 Fujifilm Holdings
- 12.14.1 Fujifilm Holdings Company Information
- 12.14.2 Fujifilm Holdings Business Overview
- 12.14.3 Fujifilm Holdings Revenue in Covid-19 Treatment Business (2021-2026)
- 12.14.4 Fujifilm Holdings Covid-19 Treatment Product Portfolio
- 12.14.5 Fujifilm Holdings Recent Developments
- 12.15 Zhejiang Hisun Pharmaceutical Co. Ltd
- 12.15.1 Zhejiang Hisun Pharmaceutical Co. Ltd Company Information
- 12.15.2 Zhejiang Hisun Pharmaceutical Co. Ltd Business Overview
- 12.15.3 Zhejiang Hisun Pharmaceutical Co. Ltd Revenue in Covid-19 Treatment Business (2021-2026)
- 12.15.4 Zhejiang Hisun Pharmaceutical Co. Ltd Covid-19 Treatment Product Portfolio
- 12.15.5 Zhejiang Hisun Pharmaceutical Co. Ltd Recent Developments
- 12.16 Roche
- 12.16.1 Roche Company Information
- 12.16.2 Roche Business Overview
- 12.16.3 Roche Revenue in Covid-19 Treatment Business (2021-2026)
- 12.16.4 Roche Covid-19 Treatment Product Portfolio
- 12.16.5 Roche Recent Developments
- 12.17 Sanofi
- 12.17.1 Sanofi Company Information
- 12.17.2 Sanofi Business Overview
- 12.17.3 Sanofi Revenue in Covid-19 Treatment Business (2021-2026)
- 12.17.4 Sanofi Covid-19 Treatment Product Portfolio
- 12.17.5 Sanofi Recent Developments
- 12.18 Pfizer
- 12.18.1 Pfizer Company Information
- 12.18.2 Pfizer Business Overview
- 12.18.3 Pfizer Revenue in Covid-19 Treatment Business (2021-2026)
- 12.18.4 Pfizer Covid-19 Treatment Product Portfolio
- 12.18.5 Pfizer Recent Developments
- 12.19 Eli Lilly
- 12.19.1 Eli Lilly Company Information
- 12.19.2 Eli Lilly Business Overview
- 12.19.3 Eli Lilly Revenue in Covid-19 Treatment Business (2021-2026)
- 12.19.4 Eli Lilly Covid-19 Treatment Product Portfolio
- 12.19.5 Eli Lilly Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst